Par Drugs and Chemicals Limited
NSE: PAR
Prev Close
97.1
Open Price
96.15
Volume
2,800
Today Low / High
96 / 97.15
52 WK Low / High
81.01 / 348.45
Range
92 - 101
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 96.5, with a change of -0.6 (-0.61792%). The expected target range on the NSE is between 92 - 101. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
Par Drugs and Chemicals Limited Graph
Par Drugs and Chemicals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Par Drugs and Chemicals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 96.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 96.50 | 97.47 | 87.72 - 107.21 |
98.43 | 78.74 - 118.12 | ||
99.40 | 69.58 - 129.21 | ||
Bearish Scenario | 96.50 | 95.54 | 85.98 - 105.09 |
94.57 | 75.66 - 113.48 | ||
93.61 | 65.52 - 121.69 |
Overview of Par Drugs and Chemicals Limited
ISIN
INE04LG01015
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
7,422
Market Cap
1,187,393,900
Last Dividend
0
Official Website
IPO Date
2019-05-30
DCF Diff
-126.60
DCF
228
Financial Ratios Every Investor Needs
Stock Dividend of PAR
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2021-11-22 | November 22, 21 | 1.25 | 1.25 | 2021-11-23 | 2021-12-09 | |
2020-07-10 | July 10, 20 | 0.625 | 1.25 | 2020-07-13 | 2020-08-20 | |
2019-11-22 | November 22, 19 | 0.625 | 1.25 | 2019-11-25 | 2019-12-11 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 100.97 Cr | 38.13 Cr | 62.84 Cr | 0.6224 | 0.00 Cr | 0.00 Cr | 56.99 Cr | 13.36 Cr | 10.86 | 19.50 Cr | 0.1323 |
2024-03-31 | 95.64 Cr | 34.65 Cr | 60.99 Cr | 0.6377 | 0.11 Cr | 1.64 Cr | 55.16 Cr | 14.50 Cr | 11.78 | 22.95 Cr | 0.1516 |
2023-03-31 | 95.10 Cr | 66.40 Cr | 28.69 Cr | 0.3017 | 0.10 Cr | 1.24 Cr | 14.97 Cr | 11.33 Cr | 9.21 | 18.21 Cr | 0.1192 |
2022-03-31 | 74.20 Cr | 49.86 Cr | 24.34 Cr | 0.3280 | 0.01 Cr | 1.46 Cr | 12.97 Cr | 9.21 Cr | 7.49 | 16.25 Cr | 0.1242 |
2021-03-31 | 59.88 Cr | 37.44 Cr | 22.44 Cr | 0.3748 | 0.10 Cr | 0.79 Cr | 13.19 Cr | 11.61 Cr | 9.45 | 18.19 Cr | 0.1939 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 27.58 Cr | 119.39 Cr | 20.42 Cr | 98.9749 Cr | 0.00 Cr | -27.58 Cr | 6.11 Cr | 38.91 Cr | 0.00 Cr | 0.00 Cr | 25.07 Cr | 16.5685 Cr |
2024-03-31 | 36.65 Cr | 101.61 Cr | 15.98 Cr | 85.6320 Cr | 0.00 Cr | -36.65 Cr | 4.42 Cr | 41.33 Cr | 0.00 Cr | 0.00 Cr | 0.01 Cr | 12.4391 Cr |
2023-03-31 | 22.24 Cr | 88.87 Cr | 17.63 Cr | 71.2383 Cr | 0.00 Cr | -22.24 Cr | 5.38 Cr | 38.69 Cr | 0.06 Cr | 0.00 Cr | 0.01 Cr | 13.9894 Cr |
2022-03-31 | 16.21 Cr | 78.69 Cr | 18.81 Cr | 59.8772 Cr | 0.00 Cr | -16.21 Cr | 4.71 Cr | 34.35 Cr | 0.01 Cr | 0.00 Cr | 0.01 Cr | 14.8574 Cr |
2021-03-31 | 21.16 Cr | 76.38 Cr | 24.17 Cr | 52.2145 Cr | 8.32 Cr | -12.84 Cr | 3.00 Cr | 34.37 Cr | 4.65 Cr | 4.79 Cr | 0.01 Cr | 15.9792 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 16.1602 Cr | -25.2370 Cr | 0.0000 Cr | 14.9336 Cr | -9.0767 Cr | 27.5772 Cr | -1.2266 Cr | 13.3579 Cr | 0.0000 Cr | 0.0000 Cr | -1.9289 Cr |
2024-03-31 | 20.2489 Cr | -5.8381 Cr | 0.0000 Cr | 14.1686 Cr | 14.4109 Cr | 36.6539 Cr | -6.0803 Cr | 14.5010 Cr | 0.0000 Cr | 0.0000 Cr | 1.2019 Cr |
2023-03-31 | 13.3771 Cr | -7.3381 Cr | -0.0024 Cr | 5.7435 Cr | 6.0366 Cr | 22.2430 Cr | -7.6336 Cr | 15.0792 Cr | 0.0000 Cr | 0.0000 Cr | -0.6662 Cr |
2022-03-31 | 7.6152 Cr | -3.0184 Cr | -9.5542 Cr | 4.4129 Cr | -4.9574 Cr | 16.2064 Cr | -3.2023 Cr | 12.7032 Cr | -7.6396 Cr | -1.5381 Cr | -1.7160 Cr |
2021-03-31 | 12.0851 Cr | 0.0507 Cr | 1.6489 Cr | 7.0359 Cr | 13.7847 Cr | 21.1638 Cr | -5.0491 Cr | 14.7261 Cr | 3.0206 Cr | -0.7690 Cr | -0.0799 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2025-06-30 | 26.05 Cr | 11.34 Cr | 14.71 Cr | 0.5648 | 2.66 Cr | 3.33 Cr | 2.70 | 5.40 Cr | 0.1278 |
2025-03-31 | 22.33 Cr | 9.78 Cr | 12.55 Cr | 0.5621 | 10.64 Cr | 1.65 Cr | 1.34 | 2.42 Cr | 0.0739 |
2024-12-31 | 21.38 Cr | 8.81 Cr | 12.57 Cr | 0.5880 | 0.51 Cr | 0.58 Cr | 0.47 | 1.70 Cr | 0.0270 |
2024-09-30 | 34.66 Cr | 14.33 Cr | 20.33 Cr | 0.5866 | 10.50 Cr | 8.60 Cr | 6.99 | 12.42 Cr | 0.2480 |
2024-06-30 | 22.61 Cr | 7.49 Cr | 15.12 Cr | 0.6688 | 3.33 Cr | 2.53 Cr | 2.06 | 4.31 Cr | 0.1121 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 27.58 Cr | 0.00 Cr | 27.58 Cr | 16.71 Cr | 6.11 Cr | 54.86 Cr | 38.91 Cr | 119.39 Cr | 20.42 Cr |
2024-12-31 | 0.00 Cr | 0.00 Cr | 18.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -96.76 Cr |
2024-09-30 | 18.78 Cr | 0.00 Cr | 18.78 Cr | 22.98 Cr | 4.93 Cr | 49.06 Cr | 40.13 Cr | 115.65 Cr | 18.89 Cr |
2024-06-30 | -36.65 Cr | 73.31 Cr | 36.65 Cr | 0.00 Cr | 0.00 Cr | 36.65 Cr | 0.00 Cr | 0.00 Cr | -85.63 Cr |
2024-03-31 | 36.65 Cr | 3.13 Cr | 36.65 Cr | 13.71 Cr | 4.18 Cr | 59.62 Cr | 41.33 Cr | 101.61 Cr | 15.98 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 1.65 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-12-31 | 0.58 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-09-30 | 8.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-06-30 | 2.53 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 3.72 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
2021-04-27 | April 27, 21 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,641.80 | ₹3,939,137,904,000.00 | ₹2,098,310.00 |
Divi's Laboratories Limited | DIVISLAB | ₹6,151.50 | ₹1,633,032,553,500.00 | ₹681,524.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,685.30 | ₹1,247,271,358,500.00 | ₹279,865.00 |
Mankind Pharma Limited | MANKIND | ₹2,606.80 | ₹1,075,901,331,568.00 | ₹731,363.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,277.60 | ₹1,063,387,459,020.00 | ₹1,229,920.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹988.80 | ₹994,960,224,000.00 | ₹307,423.00 |
Lupin Limited | LUPIN | ₹1,974.70 | ₹901,938,300,900.00 | ₹380,574.00 |
Alkem Laboratories Limited | ALKEM | ₹5,426.00 | ₹648,759,690,000.00 | ₹99,592.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,050.40 | ₹610,074,420,800.00 | ₹1,872,943.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,937.30 | ₹546,707,997,300.00 | ₹466,930.00 |
Laurus Labs Limited | LAURUSLABS | ₹879.10 | ₹474,560,157,500.00 | ₹1,548,015.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,418.40 | ₹359,853,753,600.00 | ₹437,422.00 |
Cohance Lifesciences Limited | COHANCE | ₹884.70 | ₹338,457,031,978.00 | ₹105,334.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,638.50 | ₹329,643,636,000.00 | ₹51,046.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,747.90 | ₹273,268,433,900.00 | ₹250,995.00 |
Piramal Enterprises Limited | PEL | ₹1,167.70 | ₹264,691,900,600.00 | ₹185,928.00 |
Eris Lifesciences Limited | ERIS | ₹1,768.70 | ₹240,909,320,900.00 | ₹37,828.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,479.40 | ₹240,371,432,600.00 | ₹246,897.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,433.00 | ₹210,825,000,000.00 | ₹11,150.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹974.60 | ₹191,570,299,800.00 | ₹29,523.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹13,888.00 | ₹178,181,651,200.00 | ₹28,485.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹1,083.00 | ₹172,501,323,000.00 | ₹140,483.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,168.10 | ₹164,800,966,770.00 | ₹172,520.00 |
NATCO Pharma Limited | NATCOPHARM | ₹882.45 | ₹158,055,619,500.00 | ₹259,207.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹458.50 | ₹111,252,274,000.00 | ₹945,653.00 |
Procter & Gamble Health Limited | PGHL | ₹6,581.50 | ₹109,248,951,100.00 | ₹46,180.00 |
Shilpa Medicare Limited | SHILPAMED | ₹851.90 | ₹83,308,067,710.00 | ₹36,218.00 |
Strides Pharma Science Limited | STAR | ₹865.50 | ₹79,775,471,850.00 | ₹92,524.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹863.25 | ₹78,240,335,715.00 | ₹294,146.00 |
FDC Limited | FDC | ₹474.65 | ₹77,277,766,500.00 | ₹198,260.00 |
Innova Captab Limited | INNOVACAP | ₹911.35 | ₹52,151,939,956.00 | ₹70,484.00 |
Suven Life Sciences Limited | SUVEN | ₹230.75 | ₹50,320,575,500.00 | ₹56,145.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹146.08 | ₹47,406,173,760.00 | ₹195,028.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹483.05 | ₹44,087,973,500.00 | ₹160,183.00 |
Sequent Scientific Limited | SEQUENT | ₹175.85 | ₹44,021,409,750.00 | ₹240,114.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹772.20 | ₹39,165,289,020.00 | ₹31,345.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,358.20 | ₹39,002,269,800.00 | ₹5,512.00 |
Gufic Biosciences Limited | GUFICBIO | ₹363.25 | ₹36,425,983,500.00 | ₹39,528.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹502.80 | ₹35,400,036,240.00 | ₹9,588.00 |
Hikal Limited | HIKAL | ₹254.90 | ₹31,429,424,900.00 | ₹3,142,496.00 |
Solara Active Pharma Sciences Limited | SOLARA | ₹631.60 | ₹30,413,434,800.00 | ₹53,896.00 |
IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹96.82 | ₹28,419,284,140.00 | ₹850,181.00 |
Alembic Limited | ALEMBICLTD | ₹105.52 | ₹27,095,636,534.00 | ₹249,048.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹49.03 | ₹26,866,184,620.00 | ₹2,370,089.00 |
Indoco Remedies Limited | INDOCO | ₹279.55 | ₹25,787,900,445.00 | ₹12,570.00 |
Key Executives
Gender: male
Year Born: 1974
Gender: male
Year Born: 1990
Gender: male
Year Born: 1977
Gender: male
Year Born: 1983
FAQs about Par Drugs and Chemicals Limited
The CEO is Jignesh Vallabhbhai Savani.
The current price is ₹96.50.
The range is ₹81.01-348.45.
The market capitalization is ₹118.74 crores.
The P/E ratio is 8.40.
The company operates in the Healthcare sector.
Overview of Par Drugs and Chemicals Limited (ISIN: INE04LG01015) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹118.74 crores and an average daily volume of 7,422 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.